Condiciones de salud que hesperidina puede ayudar a apoyar.
Hesperidin suppresses allergic airway inflammation through inhibition of NF-κB, reduction of Th2 cytokines (IL-4, IL-5, IL-13), mast cell stabilization, and eosinophil suppression—all mechanisms relevant to respiratory allergies including allergic rhinitis and allergic asthma. Evidence is primarily preclinical; no standalone human RCTs for respiratory allergies have been identified.
Hesperidin is recognized as a potent natural antioxidant that scavenges reactive oxygen species (ROS), enhances endogenous antioxidant enzyme activity (SOD, CAT, GSH), and activates the ERK/Nrf2 signaling pathway. These effects have been demonstrated in vitro, in animal studies, and in human RCTs measuring oxidative stress biomarkers.
Hesperidin is a citrus flavanone (from orange peel) with documented endothelial-protective effects. Life Extension's cardiovascular protocol listed hesperidin from citrus peel among anti-atherogenic polyphenols with endothelial benefits. RCTs show hesperidin reduces blood pressure, improves FMD, and reduces arterial inflammatory markers including hs-CRP.
Hesperidin has demonstrated anti-asthmatic effects in animal models of allergic airway inflammation by suppressing eosinophil infiltration, Th2 cytokines (IL-4, IL-5, IL-13), and airway hyperresponsiveness. A 2023 review of hesperidin in inflammatory lung diseases specifically included a schematic representation of hesperidin's ability to reduce asthma symptoms in allergic airway models. Human RCT data for asthma are absent.
Multiple RCTs and meta-analyses have examined hesperidin's effect on blood pressure with mixed but partially positive results. One 2023 dose-response meta-analysis found a significant reduction in systolic blood pressure (SBP), while diastolic BP was unaffected. A 2024 meta-analysis of nine RCTs (n=2,414) did not find statistically significant SBP changes, illustrating ongoing controversy. The CITRUS study (n=159) demonstrated that 12 weeks of hesperidin at 345–600 mg/day decreased SBP in people with elevated or stage-1 hypertension.
Human RCT evidence for hesperidin on fasting blood glucose (FBG) is conditional and dose-dependent. A 2024 updated meta-analysis of RCTs found a small but significant reduction in FBG (WMD: −0.15 mg/dL) and improvement in the quantitative insulin sensitivity check index (QUICKI). Effects are more pronounced at doses >500 mg/day, durations >6 weeks, and in individuals with impaired baseline FBG.
Hesperidin promotes osteogenesis by upregulating osteogenic markers and organizing collagen matrix in bone tissue. A clinical trial (NCT01881204) evaluated hesperidin combined with calcium for bone health in postmenopausal women. Preclinical studies in diabetic rats show hesperidin reduces pro-inflammatory bone resorption markers and increases bone turnover markers osteocalcin and osteopontin.
Multiple meta-analyses of RCTs support hesperidin's ability to reduce LDL and total cholesterol. A 2024 meta-analysis of nine RCTs (n=2,414) found significant reductions in LDL (p=0.005) and total cholesterol (p<0.00001). Effects are more pronounced with doses above 500 mg/day and treatment duration longer than six weeks. An earlier 2019 meta-analysis found no significant effect, illustrating that study quality and heterogeneity materially affect pooled conclusions.
Hesperidin suppresses multiple pro-inflammatory mediators including TNF-α, IL-1β, IL-6, NF-κB, iNOS, and COX-2 in both in vitro and clinical studies. A meta-analysis of RCTs found significant reduction in TNF-α with hesperidin supplementation. A 2024 updated meta-analysis of RCTs also confirmed significant reductions in CRP and adhesion molecules ICAM-1 and VCAM-1.
Hesperidin is a well-established venotonic agent used clinically, typically in combination with diosmin, for chronic venous insufficiency (CVI) and microcirculatory disorders. It reduces venous inflammation, improves capillary permeability, and reduces edema. The diosmin/hesperidin combination is considered a standard reference therapy for CVI in clinical trials.
A limited number of clinical trials have shown hesperidin-enriched dietary supplements significantly improve cerebral blood flow, cognition, and memory performance in older adults. Preclinical data consistently show neuroprotection in Alzheimer's and aging-related models. Most human evidence derives from orange flavanone-enriched supplementation trials rather than pure hesperidin RCTs.
Hesperidin protects and supports connective tissue by inhibiting matrix metalloproteinases (MMPs), elastase, and hyaluronidase—enzymes that degrade collagen, elastin, and hyaluronic acid. In vitro studies with human dermal fibroblasts show hesperidin reduces MMP-1 and MMP-2 expression and inhibits elastase and hyaluronidase activity, preserving extracellular matrix integrity.
Hesperidin has been studied in the context of biological aging, immune function, and oxidative-inflammatory state. A randomized controlled trial found a hesperidin-containing supplement blend decreased biological age markers and improved immunity and redox state in adults aged 30–63. Its antioxidant, anti-inflammatory, and neuroprotective properties collectively support healthy aging.
Hesperidin exhibits multiple cardioprotective actions supported by clinical and preclinical evidence: it reduces LDL, total cholesterol, and triglycerides; lowers SBP; improves endothelial function; and reduces inflammatory markers such as TNF-α, CRP, and adhesion molecules. A 2024 systematic review confirmed benefits in blood pressure, endothelial function, and inflammatory markers from clinical trials.
Hesperidin is a flavanone glycoside that is the key co-component of MPFF (micronized purified flavonoid fraction) with diosmin, supported by meta-analyses and multiple RCTs for hemorrhoidal disease. A 2021 PMC retrospective study using a hesperidin-containing compound achieved 89.8% grade reduction in hemorrhoid severity (p<0.001) in 49 patients.
Hesperidin has shown improvement of the quantitative insulin sensitivity check index (QUICKI) in a 2024 meta-analysis of RCTs. In vitro evidence demonstrates hesperidin alleviates insulin resistance in human hepatocytes. Effects are primarily observed in higher-risk populations at doses above 500 mg/day for at least 6 weeks.
Hesperidin demonstrates renoprotective effects in multiple preclinical models of kidney injury including nephrotoxin-induced, hypertension-related, and oxidative-stress-related renal damage. It reduces renal oxidative stress markers, serum ACE activity, and TGF-β1, and modulates angiotensin receptor expression to protect kidney function. Human clinical data specific to kidney endpoints are absent.
Hesperidin exerts hepatoprotective effects by reducing oxidative stress, inhibiting hepatic stellate cell activation and fibrosis, and protecting against chemical-induced liver injury in preclinical models. It maintains glutathione (GSH) and catalase activity and reduces lipid peroxidation (MDA) in liver tissue. Evidence is primarily preclinical with robust animal data.
Hesperidin demonstrates protective effects against a range of inflammatory lung conditions including COPD, pulmonary fibrosis, ARDS, and COVID-19-related lung injury in preclinical models. It inhibits NF-κB, iNOS, and COX-2-driven airway inflammation and activates the ERK/Nrf2 antioxidant pathway in lung tissue. Human clinical evidence is limited; most data are from animal models.
Human clinical trial data indicate that hesperidin-enriched supplement consumption improves memory performance and cognitive function, particularly in older adults. Animal models confirm memory-enhancing effects via hippocampal neurogenesis, cholinergic function improvement, and BDNF elevation. Hesperidin reduces memory impairment in multiple preclinical paradigms.
Hesperidin has been directly studied in patients with metabolic syndrome (MetS) in at least one double-blind RCT and is mechanistically positioned to address multiple MetS components including dyslipidemia, hyperglycemia, inflammation, and elevated blood pressure. Preclinical and emerging clinical studies support its role in MetS management.
Hesperidin, a citrus flavanone, is explicitly cited by the NIH/NCCIH and CDC Yellow Book as a bioactive compound for which at least one study has suggested benefit in motion sickness. Preclinical research in mice (Neurochemical Research 2019) demonstrated hesperidin significantly reduced motion sickness symptoms by inhibiting histamine release and downregulating histamine H1 receptor expression, with an effect comparable to dimenhydrinate at 80 mg/kg.
Hesperidin exhibits neuroprotective properties relevant to peripheral and central nerve health via antioxidant, anti-inflammatory, and anti-apoptotic mechanisms. Preclinical studies show hesperidin protects dopaminergic neurons in Parkinson's models and reduces diabetic neuropathy-associated nerve damage. Diabetic neuropathy models show hesperidin preserves nerve function through reduction of oxidative and inflammatory stress.
Hesperidin is a citrus flavanone glycoside found in orange peel with multiple preclinical anti-osteoporotic effects. It promotes osteogenesis of mesenchymal stem cells, improves bone volume ratio and thickness in ovariectomized mouse osteoporosis models, and inhibits bone resorption. The Frontiers in Nutrition (2024) nutraceuticals in osteoporosis review specifically identified hesperidin's protective role in bone health.
Hesperidin has been studied extensively in preclinical Parkinson's disease models. It protects dopaminergic neurons in the substantia nigra, modulates serotonergic and kappa-opioid receptors, enhances dopamine and its metabolites, and reduces oxidative stress and neuroinflammation. Human clinical data are lacking; evidence is currently preclinical.
Hesperidin is a flavanone glycoside identified in PMC peer-reviewed reviews as having therapeutic potential for psoriasis, with anti-inflammatory and antiproliferative properties relevant to psoriatic pathology. Preclinical evidence supports suppression of NF-κB, pro-inflammatory cytokines, and keratinocyte proliferation. Evidence is primarily preclinical.
Hesperidin exhibits anti-allergic properties by inhibiting mast cell degranulation, reducing histamine release, and suppressing IgE-mediated responses and Th2 cytokines. These mechanisms are directly relevant to seasonal allergic (type I hypersensitivity) reactions. Evidence is primarily preclinical; human clinical trial data for seasonal allergies specifically are limited.
Hesperidin inhibits enzymes (elastase, MMP-1, MMP-2) that degrade skin structural proteins and has been studied in human dermal fibroblast models for anti-aging effects. Hesperidin methyl chalcone (HMC), a related derivative, is used in cosmeceutical formulations and has shown elevated collagen I levels in preclinical models. In vitro data with human cells are supportive but in-human clinical trial data remain limited.
Hesperidin is a citrus flavanone glycoside clinically studied for chronic venous insufficiency (including spider veins) alone and in combination with diosmin. It reduces capillary permeability, strengthens vein walls, and has anti-inflammatory effects. The diosmin/hesperidin combination (MPFF) is one of the most established venoactive treatments in European guidelines, and a ConsumerLab-cited study specifically involved telangiectasia patients.
Hesperidin is a flavanone glycoside in citrus peel identified in the 2016 Phytotherapy Research thermogenic review as a non-stimulant thermogenic flavonoid that facilitates energy metabolism and weight management when combined with other thermogenic agents. Preclinical and human studies support its fat-oxidizing and anti-obesity effects.
Clinical RCTs and meta-analyses demonstrate that hesperidin significantly reduces serum triglyceride (TG) levels. A 2024 meta-analysis of nine RCTs found significant TG reduction (p=0.03). A randomized double-blind trial in 80 post-coronary artery bypass graft (CABG) patients showed 200 mg/day hesperidin for 12 weeks significantly reduced TG vs. placebo. Mechanistically, hesperidin activates LPL and reduces hepatic TG synthesis.
Hesperidin is a citrus flavanone glycoside used in combination with diosmin (as MPFF) as a first-line venoactive treatment for chronic venous disease including varicose veins. The combination diosmin-hesperidin has been shown in RCTs and meta-analyses to reduce limb swelling and improve quality of life versus placebo in CVI. Hesperidin alone and in combination contributes to venous tone improvement, reduced capillary permeability, and anti-inflammatory effects in the venous system.
Hesperidin, primarily as part of the diosmin/hesperidin combination, is clinically used to reduce edema and fluid retention associated with chronic venous insufficiency. Its venotonic and capillary-sealing properties reduce pathological capillary leakage, a primary driver of tissue edema and fluid imbalance in venous disorders.
Hesperidin accelerates wound healing in preclinical models by enhancing angiogenesis (via VEGF-c and Ang-1/Tie-2 signaling), promoting epithelial proliferation, upregulating TGF-β/Smad pathways, and reducing wound oxidative stress. Diabetic wound healing models show particularly robust results. Animal evidence is strong; human clinical trial data are limited.
Volver